biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
05:35 One-time immune cell therapy held MS steady in early trial, maker says✦05:44 Lilly moves a Zepbound add-on that boosted weight loss into big trials✦05:43 Own tumor immune cells plus Keytruda made melanoma vanish on scans in 29%✦05:39 DNA of 8 long-lived bat species ties virus defenses to long life✦05:36 Cholesterol pills cut heart problems in healthy older people, not dementia✦05:32 One-time gene therapy for Duchenne muscle disease met its main trial goal✦05:40 Adding a second immune drug cut death risk 58% in deadly lung cancer trial✦05:27 Custom-made melanoma vaccine cut risk of return or death 42% in big trial✦05:35 One-time immune cell therapy held MS steady in early trial, maker says✦05:44 Lilly moves a Zepbound add-on that boosted weight loss into big trials✦05:43 Own tumor immune cells plus Keytruda made melanoma vanish on scans in 29%✦05:39 DNA of 8 long-lived bat species ties virus defenses to long life✦05:36 Cholesterol pills cut heart problems in healthy older people, not dementia✦05:32 One-time gene therapy for Duchenne muscle disease met its main trial goal✦05:40 Adding a second immune drug cut death risk 58% in deadly lung cancer trial✦05:27 Custom-made melanoma vaccine cut risk of return or death 42% in big trial
← People to follow
Georgina Long
Photo: Johnorchard, CC BY-SA 4.0, via Wikimedia Commons
PERSON TO FOLLOW

Georgina Long

Medical director, Melanoma Institute Australia; University of Sydney

Medical oncologist and chair of melanoma medical oncology and translational research at the University of Sydney. She was the global principal investigator of the late-stage trial of Moderna and Merck's personalized mRNA melanoma vaccine and presented its results at the 2026 European Society for Medical Oncology congress.

melanomacancer vaccinesimmunotherapyclinical trials

WHAT TO WATCHPublication of the full trial in the New England Journal of Medicine and later survival results.

ON THE WIRE

Every story about Georgina’s work.

Profile sources

  1. 1
    World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial ScienceAlert
  2. 2
    Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium - Merck.com Merck.com